vs
Side-by-side financial comparison of GERON CORP (GERN) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Syndax Pharmaceuticals Inc is the larger business by last-quarter revenue ($68.5M vs $47.2M, roughly 1.5× GERON CORP). GERON CORP runs the higher net margin — -39.0% vs -99.3%, a 60.3% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 67.1%).
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
GERN vs SNDX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $68.5M |
| Net Profit | $-18.4M | $-68.0M |
| Gross Margin | — | — |
| Operating Margin | -29.4% | -91.3% |
| Net Margin | -39.0% | -99.3% |
| Revenue YoY | 67.1% | 791.7% |
| Net Profit YoY | 30.3% | 27.8% |
| EPS (diluted) | $-0.03 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $68.5M | ||
| Q3 25 | $47.2M | $45.9M | ||
| Q2 25 | $49.0M | $38.0M | ||
| Q1 25 | $39.6M | $20.0M | ||
| Q3 24 | $28.3M | $12.5M | ||
| Q2 24 | $882.0K | — | ||
| Q1 24 | $304.0K | $0 | ||
| Q4 23 | $23.0K | — |
| Q4 25 | — | $-68.0M | ||
| Q3 25 | $-18.4M | $-60.7M | ||
| Q2 25 | $-16.4M | $-71.8M | ||
| Q1 25 | $-19.8M | $-84.8M | ||
| Q3 24 | $-26.4M | $-84.1M | ||
| Q2 24 | $-67.4M | — | ||
| Q1 24 | $-55.4M | $-72.4M | ||
| Q4 23 | — | — |
| Q4 25 | — | -91.3% | ||
| Q3 25 | -29.4% | -125.2% | ||
| Q2 25 | -25.4% | -182.7% | ||
| Q1 25 | -42.2% | -417.9% | ||
| Q3 24 | -99.8% | -716.6% | ||
| Q2 24 | -7860.9% | — | ||
| Q1 24 | -18465.1% | — | ||
| Q4 23 | — | — |
| Q4 25 | — | -99.3% | ||
| Q3 25 | -39.0% | -132.4% | ||
| Q2 25 | -33.4% | -189.3% | ||
| Q1 25 | -50.1% | -423.3% | ||
| Q3 24 | -93.5% | -673.0% | ||
| Q2 24 | -7639.8% | — | ||
| Q1 24 | -18220.4% | — | ||
| Q4 23 | — | — |
| Q4 25 | — | $-0.78 | ||
| Q3 25 | $-0.03 | $-0.70 | ||
| Q2 25 | $-0.02 | $-0.83 | ||
| Q1 25 | $-0.03 | $-0.98 | ||
| Q3 24 | $-0.04 | $-0.98 | ||
| Q2 24 | $-0.10 | — | ||
| Q1 24 | $-0.09 | $-0.85 | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.1M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $248.7M | $64.6M |
| Total Assets | $567.4M | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $394.1M | ||
| Q3 25 | $78.1M | $436.0M | ||
| Q2 25 | $77.7M | $455.2M | ||
| Q1 25 | $83.7M | $512.2M | ||
| Q3 24 | $60.3M | $389.6M | ||
| Q2 24 | $116.9M | — | ||
| Q1 24 | $189.8M | $434.6M | ||
| Q4 23 | $70.0M | — |
| Q4 25 | — | $64.6M | ||
| Q3 25 | $248.7M | $115.4M | ||
| Q2 25 | $259.5M | $157.4M | ||
| Q1 25 | $268.2M | $215.1M | ||
| Q3 24 | $292.3M | $366.4M | ||
| Q2 24 | $306.7M | — | ||
| Q1 24 | $344.9M | $491.9M | ||
| Q4 23 | $247.9M | — |
| Q4 25 | — | $529.7M | ||
| Q3 25 | $567.4M | $551.8M | ||
| Q2 25 | $555.2M | $596.1M | ||
| Q1 25 | $562.5M | $640.7M | ||
| Q3 24 | $444.9M | $425.8M | ||
| Q2 24 | $449.4M | — | ||
| Q1 24 | $482.1M | $543.0M | ||
| Q4 23 | $394.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.6M | $-69.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-69.5M | ||
| Q3 25 | $-13.6M | $-70.5M | ||
| Q2 25 | $-27.4M | $-87.8M | ||
| Q1 25 | $-48.0M | $-95.2M | ||
| Q3 24 | $-58.9M | $-62.3M | ||
| Q2 24 | $-53.5M | — | ||
| Q1 24 | $-62.3M | $-83.5M | ||
| Q4 23 | $-167.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-53.7M | — | ||
| Q1 24 | $-62.9M | — | ||
| Q4 23 | $-168.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6086.6% | — | ||
| Q1 24 | -20680.3% | — | ||
| Q4 23 | -732926.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 202.3% | — | ||
| Q4 23 | 3608.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
